Scenic Biotech

Scenic Biotech, founded in 2017, is a private, preclinical-stage biotech developing a novel class of therapeutics based on genetic modifiers. The company's core innovation is its proprietary Cell-Seq discovery platform, which identifies 'hidden disease protection factors' within the genome to rebalance disease pathways, rather than directly correcting the primary genetic defect. This approach has generated a wholly-owned pipeline of small molecule programs and attracted strategic collaborations with major pharmaceutical partners like Alnylam, Bristol Myers Squibb, and Genentech. Scenic is positioned at the forefront of a new therapeutic paradigm with potential applications across a range of severe genetic conditions.

Proprietary Cell-Seq™ discovery platform designed to identify genetic modifiers ('hidden disease protection factors') that can neutralize the impact of primary disease-causing mutations, enabling the discovery of novel druggable targets.

Scenic operates in the competitive genetic medicine space, facing rivals using gene therapy, gene editing, and antisense oligonucleotides to directly target disease genes. Its unique focus on modifier genes via small molecules differentiates it, but it must prove its approach can achieve efficacy comparable or superior to these established modalities.